Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib + R-CHOP in Newly Diagnosed Non-GCB DLBCL
NCT04835870Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Apr 2021
- Primary completion
- Oct 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by First Affiliated Hospital of Soochow University. Status: unknown.
02
Drugs
zanubrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04835870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04835870.